Barroso-Sousa R, Vaz-Luis I, Di Meglio A, Hu J, Li T, Rees R, Sinclair N, Milisits L, Leone JP, Constantine M, Faggen M, Briccetti F, Block C, Partridge A, Burstein H, Waks AG, Tayob N, Trippa L, Tolaney SM, Hassett MJ, Winer EP, Lin NU (2021) Prospective study testing a simplified Paclitaxel Premedication Regimen in patients with early breast Cancer. Oncologist 26(11):927–933. https://doi.org/10.1002/onco.13960

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31(12):1623–1649. https://doi.org/10.1016/j.annonc.2020.09.010

Article  CAS  PubMed  Google Scholar 

Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H (1996) A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the clinical Screening Group of the EORTC. Ann Oncol 7(2):165–171. https://doi.org/10.1093/oxfordjournals.annonc.a010544

Article  CAS  PubMed  Google Scholar 

Galletti G, Zhang C, Gjyrezi A, Cleveland K, Zhang J, Powell S, Thakkar PV, Betel D, Shah MA, Giannakakou P (2020) Microtubule Engagement with Taxane is altered in taxane-resistant gastric Cancer. Clin Cancer Res 26(14):3771–3783. https://doi.org/10.1158/1078-0432.CCR-19-3018

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27(22):3611–3619. https://doi.org/10.1200/JCO.2008.18.5397

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R (2022) Breast Cancer, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw 2(60):691–722. https://doi.org/10.6004/jnccn.2022.0030

Article  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Kumar R (2024) Breast Cancer, Version 3.2024, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Cancer Netw JNCCN 22(5):331–357. https://doi.org/10.6004/jnccn.2024.0035

Article  CAS  PubMed  Google Scholar 

Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching PA, Barinoff J, Holms F, Thomssen C, Zahm DM, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G (2011) Re-challenging taxanes in recurrent breast Cancer in patients treated with (Neo-)Adjuvant taxane-based therapy. Breast Care (Basel) 6(4):279–283. https://doi.org/10.1159/000330946

Article  PubMed  Google Scholar 

Hanovich E, Asmis T, Ong M, Stewart D (2020) Rechallenge Strategy in Cancer Therapy. Oncology 98(10):669–679. https://doi.org/10.1159/000507816

Article  CAS  PubMed  Google Scholar 

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714–726. https://doi.org/10.1038/nrc3599

Article  CAS  PubMed  Google Scholar 

Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, Wang X, Hao C, Yin Y, Wang S, Yan M, Wang T, Yan Y, Chen X, Song E (2022) Chinese society of clinical oncology (CSCO) breast Cancer guidelines 2022. Translational Breast Cancer Res 3:13. https://doi.org/10.21037/tbcr-22-21

Article  Google Scholar 

Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542–5551. https://doi.org/10.1200/JCO.2005.02.027

Article  CAS  PubMed  Google Scholar 

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594–601. https://doi.org/10.1200/JCO.2013.52.4892

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kucukoztas N, Oguz A, Rahatli S, Altundag O, Altundag K (2016) Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes. J buon 21(5):1076–1081

PubMed  Google Scholar 

Lansinger OM, Biedermann S, He Z, Colevas AD (2021) Do steroids Matter? A retrospective review of Premedication for Taxane Chemotherapy and hypersensitivity reactions. J Clin Oncol 39(32):3583–3590. https://doi.org/10.1200/JCO.21.01200

Article  CAS  PubMed  Google Scholar 

Lin YC, Chang HK, Wang CH, Chen JS, Liaw CC (2000) Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. Anticancer Drugs 11(8):617–621. https://doi.org/10.1097/00001813-200009000-00003

Article  CAS  PubMed  Google Scholar 

Lorusso V, Latorre A, Giotta F (2020) Chemotherapy options beyond the First line in HER-Negative metastatic breast Cancer. J Oncol 2020:9645294. https://doi.org/10.1155/2020/9645294

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V (2010) Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 21(1):48–54. https://doi.org/10.1093/annonc/mdp498

Article  CAS  PubMed  Google Scholar 

O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823. https://doi.org/10.1200/JCO.2002.09.002

Article  CAS  PubMed  Google Scholar 

Oudard S, Kramer G, Caffo O, Creppy L, Loriot Y, Hansen S, Holmberg M, Rolland F, Machiels JP, Krainer M (2015) Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. BJU Int 115(5):744–752. https://doi.org/10.1111/bju.12845

Article  CAS  PubMed  Google Scholar 

Réda M, Fouquier A, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Coudert B, Bertaut A, Ladoire S (2023) Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: clinical activity, tolerance and survival results. Breast 68:149–156. https://doi.org/10.1016/j.breast.2023.01.015

Article  PubMed  PubMed Central  Google Scholar 

Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JBC, Manunta S, Mazzarella L, Brollo J, Goldhirsch A (2012) Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol 23(3):547–555. https://doi.org/10.1093/annonc/mdr382

Article  CAS  PubMed  Google Scholar 

Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112(7):1455–1461. https://doi.org/10.1002/cncr.23321

Article  CAS  PubMed  Google Scholar 

Scribano CM, Wan J, Esbona K, Tucker JB, Lasek A, Zhou AS, Zasadil LM, Molini R, Fitzgerald J, Lager AM, Laffin JJ, Correia-Staudt K, Wisinski KB, Tevaarwerk AJ, O’Regan R, McGregor SM, Fowler AM, Chappell RJ, Bugni TS, Burkard ME, Weaver BA (2021) Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Sci Transl Med 13(610):eabd4811. https://doi.org/10.1126/scitranslmed.abd4811

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z, Rackoff WR (2009) Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27(27):4522–4529. https://doi.org/10.1126/scitranslmed.abd4811

Art